ClinicalTrials.gg
CompletedNCT05477524VALORUpdated Jun 4, 2026

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

A Phase 3 interventional study of VLA15 and Saline in Lyme Disease, sponsored by Pfizer. Completed at 129 sites in 7 countries. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
12,546
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Lyme Disease with a site in United States — 15 open to participants now, 17 under way, 2 of them phase 3. Lyme Disease · United States.

Enrollment
2nd of 33
12,546 · median 72
Started
2022
with 3 others
Phase 3
10 of 54
1 open now
Registered
41st of 54
by date
Lead sponsor
8 of 54
Pfizer

Among the 54 studies in Lyme Disease with a site in United States, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2022, is one of 10 in phase 3, and was the 41st registered.

Lyme Disease

98 studies on the registry are indexed under Lyme Disease; 27 are open to participants now.

Browse Lyme Disease studies →

Open to participants now

15 of the 54 studies in Lyme Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Lyme Disease studies recruiting now, 11 (61%) set no upper age limit and 3 (17%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 5 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lyme Disease with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence.

Participants will receive a 3-dose primary vaccination series at about 0, 2, and 5 to 9 months and then receive a booster dose about 12 months after end of primary vaccination series. Vaccination of participants will occur at a time of year such that the primary series is completed before the peak Lyme disease season followed by a booster dose just prior to the beginning of the second Lyme disease season. A subset of participants will be followed for a third Lyme disease season.

Comparison will be made between the Lyme disease cases of people receiving the study vaccine to those of the people who are not. This will help us determine if the study vaccine is safe and effective.

If enrolled, participants will need to visit the research site at least 7 times during the study, and for a subset of participants up to 9 times. There will also be at least 5 telephone contacts. It is expected that each participant will take part in this study for up to about 2 and a half years. The subset of participants followed for a third Lyme disease season will take part in this study for up to about to 3 and a half years.

03

Conditions studied

  • Lyme Disease

Browse trials for

Keywords

  • VLA15
  • Lyme Borreliosis
  • Vaccine
  • Tick
04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Participants who reside in areas with endemic Lyme disease and who lead lifestyles that put them at increased risk for Lyme disease. For example, this could include, but not be limited to:
  • Individuals who work in B burgdorferi-infected/tick-infested areas, especially those with occupations that may be associated with higher risk of exposure, such as landscaping, forestry, and wildlife and parks management.
  • Individuals who pursue recreational activities such as hiking, camping, fishing, hunting, jogging, or gardening in such areas.
  • Individuals who live on land plots with tree lines and come into contact with these trees regularly.
  • Individuals who have dogs that regularly are outdoors and frequently return with attached ticks.
  • Individuals who participate in activities in areas with tall grass, smaller wooded areas beside forests, open fields, lakesides, and riversides.

Key Exclusion Criteria:

  • Any female participants that are pregnant (or have a positive urine pregnancy test) or are breastfeeding.
  • Any diagnosis of Lyme disease within the past 3 months.
  • Any history of Lyme carditis, neuroborreliosis, or arthritis, or other disseminated Lyme disease regardless of when diagnosed.
  • Known tick bite within the past 4 weeks.
  • Newly developed or unstable underlying conditions that may interfere with the assessment of Lyme disease, including but not limited to chronic arthralgia/arthritis, second/third-degree AV heart block, chronic pain syndromes, and chronic skin conditions that reduce the ability to detect cutaneous manifestations of Lyme disease.
  • Any unstable condition with a manifestation (eg, arthritic and neurologic) that may interfere with the assessment of Lyme disease.
  • Chronic systemic doxycycline or minocycline or other tetracycline class drug use for acne or any other chronic suppressive antibiotics used to treat other conditions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12,546 participants (actual)

Study arms

  • Experimental
    VLA15 Lot 1 (3-dose primary vaccination series and booster dose)

    Shot in the deltoid muscle (preferable in the nondominant arm)

    Biological: VLA15

  • Experimental
    VLA15 Lot 2 (3-dose primary vaccination series and booster dose)

    Shot in the deltoid muscle (preferable in the nondominant arm)

    Biological: VLA15

  • Experimental
    VLA15 Lot 3 (3-dose primary vaccination series and booster dose)

    Shot in the deltoid muscle (preferable in the nondominant arm)

    Biological: VLA15

  • Placebo comparator
    Placebo (3-dose primary vaccination series and booster dose)

    Shot in the deltoid muscle (preferable in the nondominant arm)

    Other: Saline

Interventions

  • BiologicalVLA15

    Shot in the deltoid muscle (preferable in the nondominant arm)

  • OtherSaline

    Shot in the deltoid muscle (preferable in the nondominant arm)

06

What researchers measure

Primary outcomes

  1. Relative incidence rate reduction of confirmed Lyme disease cases in the VLA15 group compared to the placebo group

    A confirmed case of Lyme disease, caused by B burgdorferi sensu lato, is defined as a clinically suspected case of Lyme disease that is confirmed by PCR, culture, microbial cell-free B burgdorferi-specific DNA sequencing, or serological antiborrelial antibody assay, and finally assessed and confirmed to be a case by the independent Adjudication Committee

    Time frame: Beginning 1 month after receiving the booster dose (28 days after receiving the booster dose through the end of the Lyme disease season following the booster dose (end of October)).

  2. Percentage of participants reporting local reactions

    Time frame: Within 7 days following each study intervention administration

  3. Percentage of participants reporting systemic events

    Time frame: Within 7 days following each study intervention administration

  4. Percentage of participants reporting adverse events (AEs)

    Time frame: Through 1 month following each study intervention administration

  5. Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)

    Time frame: Through study completion, up to approximately 42 months.

  6. Percentage of participants reporting serious adverse events (SAEs)

    Time frame: Through study completion, up to approximately 42 months.

  7. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 2

    Time frame: At 1 month after completion of the primary series and the booster dose

  8. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 3

    Time frame: At 1 month after completion of the primary series and the booster dose

  9. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 2 to Lot 3

    Time frame: At 1 month after completion of the primary series and the booster dose

  10. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6)

    Immunobridging objective to determine non-inferiority between 5-17 year old and 18-44 year old participant strata using GMRs 1 month after completion of booster dose.

    Time frame: At 1 month after completion of the booster dose

  11. Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6)

    Immunobridging objective to determine non-inferiority between 5-17 year old and 18-44 year old participant strata using difference in seroresponse rates 1 month after completion of booster dose.

    Time frame: At 1 month after completion of the booster dose

Secondary outcomes

  1. Vaccine efficacy among participants enrolled from North American sites

    A confirmed case of Lyme disease, caused by B burgdorferi sensu lato, is defined as a clinically suspected case of Lyme disease that is confirmed by PCR, culture, microbial cell-free B burgdorferi-specific DNA sequencing, or serological antiborrelial antibody assay, and finally assessed and confirmed to be a case by the independent Adjudication Committee

    Time frame: Through the end of the Lyme disease season beginning 1 month after receiving the booster dose (28 days after completion of the booster dose until end of October)

  2. Vaccine efficacy among participants after primary series

    A confirmed case of Lyme disease, caused by B burgdorferi sensu lato, is defined as a clinically suspected case of Lyme disease that is confirmed by PCR, culture, microbial cell-free B burgdorferi-specific DNA sequencing, or serological antiborrelial antibody assay, and finally assessed and confirmed to be a case by the independent Adjudication Committee

    Time frame: Through the end of the Lyme disease season beginning 1 month after completing the primary series (28 days after completion of the primary series until end of October)

07

Study locations

129 sites
  • Care Access - Essex
    Essex, Connecticut 06426, United States
  • Care Access Mobile Site
    Ledyard Center, Connecticut 06339, United States
  • Care Access Mobile Site
    New London, Connecticut 06320, United States
  • Stamford Health Medical Group
    Stamford, Connecticut 06902, United States
  • Stamford Hospital
    Stamford, Connecticut 06904, United States
  • Northern Light Eastern Maine Medical Center
    Bangor, Maine 04401, United States
  • Care Access - Farmington
    Farmington, Maine 04938, United States
  • MaineHealth Pen Bay Hospital
    Rockport, Maine 04856, United States
  • Johns Hopkins
    Baltimore, Maryland 21205, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Johns Hopkins Rockland Physician Practice and Research Group
    Lutherville, Maryland 21093, United States
  • Sumit Bhutani MD LLC
    Westminster, Maryland 21157, United States
  • Woodholme Gastroenterology Associates
    Westminster, Maryland 21157, United States
  • Pediatric Associates of Fall River
    Fall River, Massachusetts 02721, United States
  • Care Access - Lakeville
    Lakeville, Massachusetts 02347, United States
  • Care Access - Melrose
    Melrose, Massachusetts 02176, United States
  • ActivMed Practices and Research
    Methuen, Massachusetts 01844, United States
  • Care Access - Briarpatch and Mobile Site
    Nantucket, Massachusetts 02554, United States
  • Care Access - Nantucket
    Nantucket, Massachusetts 02554, United States
  • Care Access Mobile Site
    Nantucket, Massachusetts 02554, United States
  • South Shore Medical Center
    Norwell, Massachusetts 02061, United States
  • Care Access Mobile Site
    Oak Bluffs, Massachusetts 02557, United States
  • Care Access - Hingham
    Rockland, Massachusetts 02370, United States
  • Care Access Mobile Site
    Sandwich, Massachusetts 02563, United States
  • Sisu BHR
    Springfield, Massachusetts 01103, United States
  • Care Access Mobile Site
    Vineyard Haven, Massachusetts 02568, United States
  • Care Access - Wareham
    Wareham, Massachusetts 02571, United States
  • South Shore Hospital
    Weymouth, Massachusetts 02190, United States
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
  • Clinical Research Institute
    Minneapolis, Minnesota 55402, United States
  • Care Access - Londonderry
    Londonderry, New Hampshire 03053, United States
  • Care Access - North Conway
    North Conway, New Hampshire 03860, United States
  • ActivMed Practices & Research, LLC.
    Portsmouth, New Hampshire 03801, United States
  • Internal Medicine Associates
    Bridgeton, New Jersey 08302, United States
  • Clinilabs
    Eatontown, New Jersey 07724, United States
  • Hunterdon Infectious Disease Specialists
    Flemington, New Jersey 08822, United States
  • Hunterdon Medical Center
    Flemington, New Jersey 08822, United States
  • Care Access - Hoboken
    Hoboken, New Jersey 07030, United States
  • IMA Clinical Research Warren
    Warren Township, New Jersey 07059, United States
  • Velocity Clinical Research, Binghamton
    Binghamton, New York 13905, United States
  • Bassett Medical Center
    Cooperstown, New York 13326, United States
  • Smith Allergy and Asthma Specialists
    Cortland, New York 13045, United States
  • Care Access - Albany
    Halfmoon, New York 12065, United States
  • Care Access Mobile Site
    Halfmoon, New York 12065, United States
  • Smith Allergy & Asthma Specialists
    Horseheads, New York 14845, United States
  • Mid Hudson Medical Research
    New Windsor, New York 12553, United States
  • Care Access Mobile Site
    Aliquippa, Pennsylvania 15001, United States
  • Care Access Mobile Site
    Clarion, Pennsylvania 16214, United States
  • TruCare Internal Medicine & Infectious Disease
    DuBois, Pennsylvania 15801, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Allegheny Health and Wellness Pavilion
    Erie, Pennsylvania 16506, United States
  • Central Erie Primary Care
    Erie, Pennsylvania 16508, United States
  • Care Access Mobile Site
    Greensburg, Pennsylvania 15601, United States
  • Care Access - Mountaintop
    Hazle Township, Pennsylvania 18202, United States
  • CCP - Kid's Way
    Hermitage, Pennsylvania 16148, United States
  • Care Access - Kingston
    Kingston, Pennsylvania 18704, United States
  • Care Access Mobile Site
    Monaca, Pennsylvania 15061, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
    Pittsburgh, Pennsylvania 15236, United States
  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair
    Pittsburgh, Pennsylvania 15243, United States
  • Care Access - Pottsville
    Pottsville, Pennsylvania 17901, United States
  • Care Access Mobile Site
    Punxsutawney, Pennsylvania 15767, United States
  • Guthrie Medical Group, P.C.
    Sayre, Pennsylvania 18840, United States
  • Robert Packer Hospital
    Sayre, Pennsylvania 18840, United States
  • Frontier Clinical Research, LLC
    Scottdale, Pennsylvania 15683, United States
  • Care Access - Scranton
    Scranton, Pennsylvania 18508, United States
  • Northeast Clinical Trials Group
    Scranton, Pennsylvania 18510, United States
  • Care Access Mobile Site
    Sharon, Pennsylvania 16146, United States
  • Frontier Clinical Research, LLC
    Smithfield, Pennsylvania 15478, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Care Access - Wilkes-Barre
    Wilkes-Barre, Pennsylvania 18702, United States
  • Care Access Mobile Site
    Yeagertown, Pennsylvania 17099, United States
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
  • Care Access Mobile Site
    New Shoreham, Rhode Island 02807, United States
  • Care Access - Warwick
    Warwick, Rhode Island 02886, United States
  • Care Access - Brattleboro - Putney Road
    Brattleboro, Vermont 05301, United States
  • Care Access - Brattleboro
    Brattleboro, Vermont 05301, United States
  • The University of Vermont Medical Center Inc.
    Burlington, Vermont 05401, United States
  • Care Access - Middlebury
    Middlebury (village), Vermont 05753, United States
  • Amherst Family Practice, P.C.
    Winchester, Virginia 22601, United States
  • University Hospital and UW Health Clinics
    Madison, Wisconsin 53792, United States
  • Marshfield Medical Center - Marshfield
    Marshfield, Wisconsin 54449, United States
  • Marshfield Medical Center - Weston
    Weston, Wisconsin 54476, United States
  • Viable Clinical Research Corporation
    Bridgewater, Nova Scotia B4V 3N2, Canada
  • Canadian Center for Vaccinology
    Halifax, Nova Scotia B3K6R8, Canada
  • Centricity Research Burlington Multispecialty
    Burlington, Ontario L7M 4Y1, Canada
  • Milestone Research Inc.
    London, Ontario N5W 6A2, Canada
  • The Ottawa Hospital - General Campus
    Ottawa, Ontario K1H 8L6, Canada
  • Bluewater Clinical Research Group Inc.
    Sarnia, Ontario N7T 4X3, Canada
  • Stouffville Medical Research Institute Inc.
    Stouffville, Ontario L4A 1H2, Canada
  • Centricity Research Toronto Manna Multispecialty
    Toronto, Ontario M9W 4L6, Canada
  • Diex Recherche Sherbrooke
    Sherbrooke, Quebec J1L 0H8, Canada
  • Diex Recherche Inc. Division Victoriaville
    Victoriaville, Quebec G6P 3Z8, Canada
  • FVR, Tampereen rokotetutkimusklinikka
    Tampere, Pirkanmaa 33100, Finland
  • FVR, Turun rokotetutkimusklinikka
    Turku, Southwest Finland 20520, Finland
  • FVR, Etelä-Helsingin rokotetutkimusklinikka
    Helsinki, Uusimaa 00100, Finland
  • FVR, Itä-Helsingin rokotetutkimusklinikka
    Helsinki, Uusimaa 00930, Finland
  • FVR, Järvenpään rokotetutkimusklinikka
    Jarvenpaa, Uusimaa 04400, Finland
  • MeVac - Meilahti Vaccine Research Center
    Helsinki, 00290, Finland
  • FVR, Kokkolan rokotetutkimusklinikka
    Kokkola, 67100, Finland
  • FVR, Porin rokotetutkimusklinikka
    Pori, 28100, Finland

Showing the first 100 of 129 sites across 7 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Dreyfus J, Munnangi S, Bengtsson C, Correia B, Figueiredo R, Stark JH, Zawora M, Riddle MS, Maguire JD, Jiang Q, Ianos C, Naredo Turrado J, Svanstrom H, Bailey S, DeKoven M. Background incidence rates of health outcomes in populations at risk for Lyme disease using US administrative claims data. Vaccine. 2024 Feb 15;42(5):1094-1107. doi: 10.1016/j.vaccine.2024.01.037. Epub 2024 Jan 22. PubMed 38262807 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Jan 2026, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2022
First posted
Jul 28, 2022
StartActual
Aug 4, 2022
Primary completionActual
Jan 7, 2026
CompletionActual
Jan 7, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05477524
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Aug 4, 2022
Primary completion
Jan 7, 2026
Completion
Jan 7, 2026
Last update
Jun 4, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VLA15

Start the discussion